Area of research
Cardiology and Cardiovascular Medicine · Surgery
Research interest
Research interests include Cardiomyopathy and Myosin Studies, Cardiovascular Function and Risk Factors, Coronary Interventions and Diagnostics, and Acute Myocardial Infarction Research.
Mavacamten in Obstructive Hypertrophic Cardiomyopathy: National Insights on Access and Safety Profile From Real-World Data.
Cardiogenic Shock Detection Using Electronic Medical Records: A Review and Blueprint for Clinical Implementation and Future Research.
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM.
Long-Term Effects of Mavacamten on Patients Based on Hypertrophic Cardiomyopathy Pathogenic Genetic Variant Status: Insights From VALOR-HCM Trial.
Inclusion of the right ventricular muscle bundle during interventricular septal measurement improves diagnostic accuracy for hypertrophic cardiomyopathy
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM
Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM
Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial
Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial.
Aficamten and Cardiopulmonary Exercise Test Performance
Exercise and cardiovascular health: A state-of-the-art review
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction
Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.
Frequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States.
Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks
Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study
Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study.
Comparative Analysis of Patient Characteristics in Cardiogenic Shock Studies
A Comparison of In-Hospital Outcomes Between the Use of Impella and IABP in Acute Myocardial Infarction Cardiogenic Shock Undergoing Percutaneous Coronary Intervention
Is FFR dead? A conversation in cardiology
SCAI expert consensus update on best practices in the cardiac catheterization laboratory
Myosin Modulation in Hypertrophic Cardiomyopathy and Systolic Heart Failure: Getting Inside the Engine.
COVID-19 Pandemic: Cardiovascular Complications and Future Implications
Considerations for cardiac catheterization laboratory procedures during the <scp>COVID</scp>‐19 pandemic perspectives from the Society for Cardiovascular Angiography and Interventions Emerging Leader Mentorship (<scp><i>SCAI ELM</i></scp>) Members and Graduates
The State of the Absorb Bioresorbable Scaffold
SCAI/HFSA clinical expert consensus document on the use of invasive hemodynamics for the diagnosis and management of cardiovascular disease
Hospital Volume Outcomes After Septal Myectomy and Alcohol Septal Ablation for Treatment of Obstructive Hypertrophic Cardiomyopathy
SCAI expert consensus statement: 2016 best practices in the cardiac catheterization laboratory: (Endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologia intervencionista; Affirmation of value by the Canadian Association of interventional cardiology–Association canadienne de cardiologie d'intervention)*
Sex Differences in Outcomes Following Percutaneous Coronary Intervention According to Age
2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care